![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, September 28, 2015 6:58:48 AM
Reportbazzar has included a new report titled “MultiCell Technologies, Inc. – Product Pipeline Review – 2015”to their offerings.
For more information on this report visit: http://www.reportbazzar.com/product/multicell-technologies-inc-product-pipeline-review-2015/
Global Markets Direct’s, ‘MultiCell Technologies, Inc. – Product Pipeline Review – 2015’, provides an overview of the MultiCell Technologies, Inc.’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of MultiCell Technologies, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– The report provides brief overview of MultiCell Technologies, Inc. including business description, key information and facts, and its locations and subsidiaries
– The report reviews current pipeline of MultiCell Technologies, Inc.’s human therapeutic division and enlists all their major and minor projects
– The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
– Special feature on out-licensed and partnered product portfolio
– The report summarizes all the dormant and discontinued pipeline projects
– Latest company statement
– Latest news and deals relating to the MultiCell Technologies, Inc.’s pipeline products
Reasons to buy
– Evaluate MultiCell Technologies, Inc.’s strategic position with total access to detailed information on its product pipeline
– Assess the growth potential of MultiCell Technologies, Inc. in its therapy areas of focus
– Identify new drug targets and therapeutic classes in the MultiCell Technologies, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
– Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
– Develop strategic initiatives by understanding the focus areas of MultiCell Technologies, Inc. and exploit collaboration and partnership opportunities
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Plan mergers and acquisitions effectively by identifying the most promising pipeline of MultiCell Technologies, Inc.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Explore the dormant and discontinued projects of MultiCell Technologies, Inc. and identify potential opportunities in those areas
– Avoid Intellectual Property Rights related issues
Request Sample: MultiCell Technologies, Inc. – Product Pipeline Review – 2015
Table Of Contents:
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
MultiCell Technologies, Inc. Snapshot 5
MultiCell Technologies, Inc. Overview 5
Key Information 5
Key Facts 5
MultiCell Technologies, Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
MultiCell Technologies, Inc. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Pipeline Products – Combination Treatment Modalities 10
Pipeline Products – Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
MultiCell Technologies, Inc. – Pipeline Products Glance 13
MultiCell Technologies, Inc. – Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
MultiCell Technologies, Inc. – Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
MultiCell Technologies, Inc. – Drug Profiles 16
(lofepramine hydrochloride + phenylalanine) 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
MCT-465 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
MCT-485 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
MCT-475 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
MultiCell Technologies, Inc. – Pipeline Analysis 20
MultiCell Technologies, Inc. – Pipeline Products by Target 20
MultiCell Technologies, Inc. – Pipeline Products by Route of Administration 21
MultiCell Technologies, Inc. – Pipeline Products by Molecule Type 22
MultiCell Technologies, Inc. – Pipeline Products by Mechanism of Action 23
MultiCell Technologies, Inc. – Recent Pipeline Updates 24
MultiCell Technologies, Inc. – Dormant Projects 26
MultiCell Technologies, Inc. – Company Statement 27
MultiCell Technologies, Inc. – Locations And Subsidiaries 30
Download more Similar Reports @
http://www.reportbazzar.com/product-category/life-sciences/pharmaceuticals/
About Us:
Reportbazzar.com is your trusted source for the most inclusive and informative assortment of market research reports designed to empower you with the latest in industry information that translates to time and cost savings for your business. We not only help you give wing to your latent business ideas but also facilitate you in taking the best informed and strategic decisions that guarantee success in your most promising business endeavors.
Contact Us:
ReportBazzar
Mary Jane
US: +1 (212) 389-6363
IND: +91 20 66528525
Email: sales@reportbazzar.com
Linkedin : https://linkedin.com/company/report-bazza
FEATURED Mawson Finland Provides Update on Exploration Activities at Rajapalot • Aug 21, 2024 9:06 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM